A phase 1 dose-finding study of X4P-001 (an oral CXCR4 inhibitor) and axitinib in patients with advanced renal cell carcinoma (RCC)

被引：5

作者：

Atkins, Michael ^{[1
]}

Joseph, Richard ^{[2
]}

Ho, Thai ^{[3
]}

Vaishampayan, Ulka ^{[4
]}

Ali, Sarah ^{[5
]}

Matrana, Marc ^{[6
]}

Alter, Robert ^{[7
]}

Edenfield, Jeff ^{[8
]}

Wang, Yan ^{[9
]}

Blanchette, Sarah ^{[9
]}

Gan, Lu ^{[9
]}

McDermott, David ^{[10
]}

机构：

[1] Georgetown Lombardi Comprehens Canc Ctr, Washington, DC USA

[2] Mayo Clin, Jacksonville, FL 32224 USA

[3] Mayo Clin, Phoenix, AZ USA

[4] Karmanos Canc Inst, Detroit, MI USA

[5] Franciscan Hlth Canc Ctr, Indianapolis, IN USA

[6] Ochsner Hlth Syst, New Orleans, LA USA

[7] Hackensack Univ Med Ctr, Hackensack, NJ USA

[8] Inst Translat Oncol Res, Greensville, SC USA

[9] X4 Pharmaceut, Cambridge, MA USA

[10] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA

来源：

关键词：

D O I：

10.1158/1535-7163.TARG-17-B201

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

B201

引用

页数：2